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Cost-effectiveness models often require the consideration of a sequence of treat-
ments. This enables the downstream implications of a treatment to be captured, and 
alternative sequences to be compared. However, when many treatments are available, 
the number of feasible sequences can be large. Also, if the objective is to maximise net 
benefit for a given ICER threshold, then a comparative analysis to identify the optimal 
sequence may not be possible. This is further compounded when using individual 
patient simulation (IPS), because of the increased computational burden compared 
with cohort approaches. The aim of this study was to undertake a systematic review 
of optimisation methods that are applicable to a treatment sequencing IPS model. 
28 key papers were identified across a range of academic subjects. Metaheuristics 
including simulated annealing, tabu search and genetic algorithms have been 
applied to simulation-optimisation problems and a bespoke review framework was 
applied to determine their appropriateness. Based on the review, a framework for 
the economic evaluation of treatment sequences was developed. The framework 
considers the requirements of a cost-effectiveness model to efficiently evaluate 
sequences, the application of the reviewed metaheuristics to determine the optimal 
sequence, and the consideration of these results within a decision-making context. 
This will be applied to a case study in rheumatoid arthritis. Alternative metaheuris-
tic algorithms will be applied in an attempt to estimate a (near) optimal treatment 
sequence. Preliminary results of these experiments will be available in time for the 
November 2014 ISPOR conference. If these methods prove successful and feasible, 
then the framework may have potential applicability to sequencing models in many 
diseases. Whether there is the capability for it to be applicable within the current 
process for decision-making organisations such as NICE remains an open question, 
however, identifying an optimal sequence in a decision problem is of interest to 
decision makers.
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BAckground: Common indirect treatment comparison (ITC) methodology in over-
active bladder involves combining absolute reduction in urge urinary incontinence 
(UUI) episodes at study endpoint (e.g., week 12) to estimate the overall treatment 
effect. Trials with differing endpoints must assume equivalence to be included in 
the network. Further, analyses of endpoint data are not sufficient to predict efficacy 
at intermediate time points (e.g. 4 or 6 weeks). We developed and tested an alternate 
methodology to utilize available intermediate time points into an ITC of published 
studies of fesoterodine and tolterodine. Methodology: Study-level mean UUI 
reduction over time can be represented as the percent reduction from baseline, 
which can be modeled as a monotonically-increasing function with a theoretical 
maximum of 100%. This function is expressed with two parameters: %red = bi*time/ 
(ci + time), where bi is the maximum possible reduction for treatment i, and ci is the 
time required to reach half the maximum reduction. The inverse %red is a linear 
function of 1/time that can be used within a Bayesian ITC framework to generate 
a placebo-adjusted indirect comparison of efficacy. conclusions: The endpoint 
results obtained from the alternate methodology were comparable to those obtained 
from an endpoint ITC. This novel methodology has the additional advantage of 
utilizing all available time point data within a single analysis, which can then be 
used to generate efficacy estimates at intermediate time points, which may be 
utilized within economic models. Limitations include unavailability of uncertainty 
estimates of the %red variable and difficulty of estimating combinations of param-
eters within functional constraints. Finally, our alternate methodology may be used 
for any longitudinal data exhibiting a monotonic increase or decrease and may be 
expanded to include a network with multiple treatments.
PRM237
bayesIaN Models foR cost-effectIveNess aNalysIs IN the PReseNce of 
stRuctuRal ZeRo costs
Baio G.
University College London, London, UK
Bayesian modelling for cost-effectiveness data has received much attention in 
both the health economics and the statistical literature, in recent years. Cost-
effectiveness data are characterised by a relatively complex structure of relation-
ships linking a suitable measure of clinical benefit (\eg QALYs) and the associated 
costs. Simplifying assumptions, such as (bivariate) normality of the underlying dis-
tributions are usually not granted, particularly for the cost variable, which is charac-
terised by markedly skewed distributions. In addition, individual-level datasets are 
often characterised by the presence of structural zeros in the cost variable. Hurdle 
models can be used to account for the presence of excess zeros in a distribution and 
have been applied in the context of cost data. We extend their application to cost-
effectiveness data, defining a full Bayesian specification which consists of a pattern 
model for the individual probability of null costs, a marginal model for the costs 
and a conditional model for the measure of effectiveness (given the observed costs). 
The model is presented using a working example to describe its main features. In 
addition, we present a R package (BCEs0) that directly implements this framework 
and can be used to run a full Bayesian cost-effectiveness analysis of individual data 
in the presence of structural zero costs for some subjects.
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Prioritisation of assessment topics is an essential activity within HTA. Failure to 
successfully identify technologies that are likely to have the greatest impact on 
the health system carries an opportunity cost that is measured in poorer decision 
tred care and integration of the patient perspective in health care policy decisions. 
A major challenge for the integration of evidence on patient preference is that 
research on patient preferences is performed by various disciplines (e.g. psychology 
and economics) that do not share a common language. It has been recommended to 
perform conceptual and taxonomic work on the definition and conceptualisation 
of ‘preference’ and related terms. The aim of this study was to develop a taxonomy 
of preference-related terms. The taxonomy was developed in three steps: 1) the 
identification of preference-related terms; 2) providing all identified terms with 
a definition from the dictionary; and 3) the identification of dominant theories 
or models from (health) economics and psychology that deal with the reference-
related terms. The proposed taxonomy consists of several building blocks that hold 
all identified preference-related terms and demonstrate the relation between terms. 
The building blocks are centred around a factual event. Ex ante to this factual event 
lies building block 1, “decision making” holding terms like “choice” and “decision”. 
Ex post lie building block 2 “evaluation process” and building block 3 “outcome of 
evaluation process”. Building block 3 holds terms like “utility”, “quality of life” and 
“satisfaction”. Building blocks 1-3 are influenced by building block 4 “the value 
system”. This value system is divided in cognition, affect and conation and holds 
terms like “beliefs”, “expectation”, “attitudes”, “desires” and “intention”. In this tax-
onomy, preferences can be considered as a part of the value system. The proposed 
taxonomy is a first step towards conceptual clarity to facilitate the integration of 
research evidence in health care policy decisions.
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Overall survival (OS) is traditionally modelled in economic evaluations of anti-cancer 
drugs. However, OS is commonly associated with problems such as immaturity of the 
data, or confounding due to treatment switching or use of inappropriate treatments 
after progression. Fortunately, analysis of historical trials reveals that there is good 
evidence across a range of cancers that the mean time in post-progression survival 
(PPS) is equal between treatment arms, i.e. Δ PPS = 0. Therefore, we recommend that 
the default position is to assume equal mean times post-progression. If there is no 
a priori biological reason to suppose that the PPS times are likely to differ between 
treatments (e.g. due to differences in cross-resistance or long term toxicities between 
treatments), our recommendation is that it should be assumed that the mean time in 
progressive disease is equal between treatment arms if any of the following apply: OS 
is very immature; treatments post-progression are substantially imbalanced between 
treatment arms; in particular, treatment switching has occurred at progression; treat-
ments post-progression are different to those routinely given in clinical practice; only 
single arm trials are available. If none of the above apply, or if there are a priorireasons 
to suggest that Δ PPS differs from 0, then the recommendation is to model OS and PFS 
in the traditional way. For chronic cancers, it is recommended that analyses should 
either assume equal times post initial treatment or equal time post progression. The 
assumption that Δ PPS = 0 substantially simplifies the economic analysis because 
cost-effectiveness becomes insensitive to OS. The methodology has been endorsed 
twice by NICE appraisal committees in assessments of drugs for chronic myeloid 
leukaemia. The cost-effectiveness of several drugs recently assessed by NICE are 
re-calculated using the methods proposed. Next, we give simplified formulae for the 
maximum drug price acceptable for reimbursement under the methodology.
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Various online services such as Socialbakers, Keyhole, Gnip offer tools to analyze, 
fetch and collect data from social media. This data is often presented in a form 
of interactive web based dashboards, displaying various trends: number of posts, 
mentions, shares, likes over time. Facebook and Twitter have an API to access data 
on social media profiles of real people. Users profiles usually have data on age, 
sex, employment and relationships status, specific group membership, etc. We 
conducted a simple feasibility study using Facebook API in diabetes area using 
profiles of people posting hashtags as a primary source of data. We then expanded 
the sample by adding people who liked, shared and reposted messages containing 
diabetes relaed hashtags #Diabetes, #dedoc, #ourD. We applied exclusion criteria 
to derive a sample consisting of patients only, hence targeting specific group of 
people. Our assumption was that people who interact with posts containing spe-
cific hashtag have diabetes. We used descriptive statistics to characterize obtained 
sample (n= 17296) by calculating mean age, age distribution histogram, proportion 
of males and females and other descriptive metrics. We also calculated conditional 
probabilities of being in multiple disease area Facebook groups such as obesity 
groups or groups of people with increased risk of cardiovascular disease. Future 
area of research will be concentrated on aspects of in-degree centrality in net-
work of diabetic people, hypothesis testing between two different groups, analyses 
of changes in positive/negative posting trends following drug launch, locating 
agents and influencers in the network and conducting prospective studies in 
social media using hashtags. Social Media data can be a valuable addition to a 
real life post launch data. Evidence on changes in positive/negative postings can 
be used as an additional piece of information in Phase IV studies or risk-sharing 
agreements.
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